KCNMA1 and central nervous system cancer: Results showed a significantly shorter median survival for dRafGOF glioma group (17 days, P < 0.0001) as compared with the control group (64 days); while dRafGOF glioma with slo RNAi groups showing extended median survival to 67 days and 58.5 days, respectively (Fig. 1f).